Screen Therapeutics LLC (formerly Envisage LLC), began its journey back in 2014 with a goal to identify, create and advance innovative products and solutions for patients. While we have faced many entrepreneurial challenges, our story is one of sheer grit and determination and we aim to make an impact in cancer immunotherapy.
We identify, build, and procure the necessary “tools” to screen drug targets and take a holistic approach in analyzing the resulting data.
Cancer - a formidable foe
Cancer continues to be a leading cause of death around the world. Despite tremendous progress being made in the development of new therapies, the incidence and prevalence of cancers have steadily risen. Moreover, access to these innovative therapies are at times limited to patients in unmet need due to either resistance to therapies or general cost of access.
Current approaches in immunotherapy are focused on activating or modulating the immune system to eradicate tumors in the tumor micro-environment (TME). While such approaches have become effective therapies for patients, the occurrence of adverse events and toxicities remain a challenge.
In TME cancer cells directly interact with both the immune system and the stroma and in turn the stroma responds with pro-inflammatory and anti-tumor makers. Understanding the cross talk between immune cells, stroma and cancer cells may lead to the discovery of novel pathways and biomarkers.
We aim to interrogate the TME for the stromal-immune-tumor factors to develop novel therapeutics for cancer.